All posts

MustGrow Biologics CEO Corey Giasson talks to Cantech Letter

Saskatoon-based MustGrow Biologics (MustGrow Biologics Stock Quote, Chart, News, Analysts, Financials TSXV:MGRO) is bringing biotechnology and regenerative agriculture together to help farmers replace synthetic chemicals and fertilizers, CEO Corey Giasson said in an Oct. 31 interview on the Cantech Letter YouTube channel.

Speaking with Ticker Take host Jon Erlichman at the 2025 Cantech Investment Conference in Toronto, Giasson said the company’s patented mustard-seed technology is now moving from research to full commercial production.

“MustGrow is an agricultural biotech company,” Giasson said. “We’ve got a patented technology around mustard that extracts compounds from mustard seed, reformulates them into biopesticides and biofertility products to help replace synthetic chemicals or fertilizers and help regenerative agriculture.”

He said the approach draws on nature’s own defences. “You eat it when you have mustard, it’s the spice that you get within the mustard, and it just so happens that it’s very effective at treating diseases and pests that farmers need to be concerned about,” he said. “It’s the natural defence mechanism of that plant.”

MUSTGROW BIOLOGICS CEO COREY GIASSON SITS DOWN WITH JON ERLICHMAN AT THE 2025 CANTECH INVESTMENT CONFERENCE

Giasson added that regulatory and consumer pressures are accelerating the shift toward biologic alternatives.

“We’re seeing significant growth,” he said. “We’ve seen quite a bit of pesticides or chemicals being banned or restricted, and farmers still have to grow crops with a finite amount of arable land. That’s what we’re bringing to the table, a natural biologic that works.”

MustGrow has also broadened its reach with the acquisition of NexusBioAg, a Canadian sales and distribution business focused on regenerative agriculture products.

“So we’re a fully integrated agriculture provider,” Giasson said.

He said the company has recently entered a new phase.

“I’m excited that we’ve turned the corner and we’re now in commercialization and sales,” Giasson said. “We’ve done about $6.6-million of revenue in the first half of this year, and we want to continue to drive that number through NexusBioAg in Canada and through TerraSante, our biofertility product registered in the United States.”

TerraSante is a wettable-powder soil additive derived from mustard seed, used to improve soil health, water capacity, and plant performance. Giasson said early demand has exceeded expectations.

“We ran out of product this spring; it’s a good problem to have, but it’s a problem,” he said. “We’re now looking to ramp up production so that we can meet demand next year. The field trials have shown positive results, and we’re starting to see repeat sales.”

-30-

Tagged with: MGRO
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Small cap stocks are still cheap, this investor says

Nationwide’s chief market strategist Mark Hackett told CNBC’s Worldwide Exchange on Dec. 3 that survey data may look weak, but… [Read More]

3 days ago

Microbot Medical is a buy, Roth says

Roth Capital Markets initiated coverage of Microbot Medical (Microbot Medical Stock Quote, Chart, News, Analysts, Financials NASDAQ:MBOT) with a “Buy”… [Read More]

3 days ago

Texas could be big for these pot stocks, analyst says

Beacon Securities analyst Russell Stanley said Texas is “getting bigger for cannabis operators” after the state’s Department of Public Safety… [Read More]

3 days ago

Bank of Nova Scotia is the cheapest bank stock, this analyst says

RBC Dominion Securities analyst Darko Mihelic said Bank of Nova Scotia’s (Bank of Nova Scotia Stock Quote, Chart, News, Analysts,… [Read More]

3 days ago

This analyst just raised his price target on Marvell Technology

Marvell Technology (Marvell Technology Stock Quote, Chart, News, Analysts, Financials NASDAQ:MRVL) reported largely in-line fiscal third-quarter results and offered longer-term… [Read More]

3 days ago

Is Curaleaf still a buy?

Beacon Securities analyst Russell Stanley maintained his “Buy” rating and C$5.00 price target on Curaleaf Holdings (Curaleaf Holdings Stock Quote,… [Read More]

3 days ago